Latest Share Chat

REMOVE ADS

Astrazeneca Share News (AZN)

Astrazeneca Information

Share Price Information for Astrazeneca (AZN)

Share Price is delayed by 15 minutes

Get Live Data

13,290.00 56.00 (0.42%)

Bid:

13,338.00

Ask:

13,344.00

Spread: 6.00 (0.045%)

Market Cap: £206.11b

Last checked at -

Intraday Astrazeneca Share Chart

REMOVE ADS

Astrazeneca News

US FDA pushes back decision on Astrazeneca's camizestrant

(Sharecast News) - Drugmaker Astrazeneca said the US Food and Drug Administration had pushed back its decision on camizestrant after requesting additi...

AstraZeneca says FDA extends breast cancer drug review period

(Alliance News) - AstraZeneca PLC on Wednesday said that the US Food & Drug Administration has extended the review period for its camizestrant filing ...

Market Reports

LONDON BRIEFING: Energy bills to rise 13%; Pets At Home cuts dividend

(Alliance News) - The price cap for household energy bills in Great Britain is set to rise by 13% from July, Pets At Home reports lower earnings and c...

Economic News

Astrazeneca's Camizestrant cleared in the EU, Enhertu and Datroway pick up fresh recommendations

(Sharecast News) - Drugmaker Astrazeneca said on Tuesday that its breast cancer treatment camizestrant has secured EU approval, while its Enhertu and ...

AstraZeneca and Daiichi cancer drugs clear regulatory hurdles

(Alliance News) - AstraZeneca PLC on Friday announced one approval and two recommendations for three products, for different cancer indications, in th...

Market Reports

CT UK Capital underperforms as underweight on AstraZeneca, Shell

(Alliance News) - CT UK Capital & Income Investment Trust PLC on Friday increased its dividend but said it underperformed the FTSE all-share index in ...

Funds

US Supreme Court rebuffs pharma challenge to Biden-era drug price

* Companies say government has dictated below-market prices

Pharmaceuticals

Citi sees buying opportunity at AstraZeneca after recent falls

(Sharecast News) - Analysts at Citi have reiterated a 'buy' rating on AstraZeneca and a 'neutral' on GSK following the European pharma sector's first-...

Broker Recommendations